Aflibercept in branch retinal vein occlusion as second line therapy: Clinical outcome 12 months after changing treatment from bevacizumab/ranibizumab-a pilot study

International Journal of Retina and Vitreous

Volumn 2, Issue 1, 2016, Pages

  Wirth, Magdalena A ^a   Becker, Matthias D ^a,b   Graf, Nicole ^c   Michels, Stephan ^a,d  

^a TRIEMLI HOSPITAL   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Graf Biostatistics   (Switzerland)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Aflibercept; Anti VEGF; Branch retinal vein occlusion; Macular edema

Indexed keywords

EID: 85013838715     PISSN: None     EISSN: 20569920     Source Type: Journal    
DOI: 10.1186/s40942-016-0045-8     Document Type: Article

References (19)

1. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513-8.
2. Haymore JG, Mejico LJ. Retinal vascular occlusion syndromes. Int Ophthalmol Clin. 2009;49(3):63-79.
3. Encke A. Pathophysiology of venous thrombosis (author's transl). Langenbecks Arch Chir. 1977;345:323-9.
4. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost. 2010;8(9):1886-94.
5. Deobhakta A, Chang LK. Inflammation in retinal vein occlusion. Int J Inflam. 2013;2013:438412.
6. Campochiaro PA, et al. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology. 2013;120(4):795-802.
7. Thach AB, et al. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology. 2014;121(5):1059-66.
8. Bressler NM, Schachat AP. Management of macular edema from retinal vein occlusions: you can never have too many choices. Ophthalmology. 2010;117(6):1061-3.
9. Campochiaro PA, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT Study. Ophthalmology. 2015;122(3):538-44. doi: 10.1016/j.ophtha.2014.08.031.
10. Papadopoulos N, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-85.
11. Holash J, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-8.
12. Evoy KE, Abel SR. Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion. Ann Pharmacother. 2013;47(6):819-27.
13. Pfau M, et al. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion. Ophthalmic Res. 2015;54(3):150-6.
14. Papakostas TD, et al. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. Eye (Lond). 2016;30(1):79-84.
15. Freund KB, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015;35(8):1489-506. doi: 10.1097/IAE.0000000000000627.
16. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046-50.
17. Rogers SL, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-1101.
18. Christoforidis JB, et al. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res. 2012;37(12):1171-4.
19. Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158(3):532-6.